Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong Sook | - |
dc.contributor.author | Jang, An Soo | - |
dc.contributor.author | Park, Sung Woo | - |
dc.contributor.author | Lee, Young Mok | - |
dc.contributor.author | Uh, Soo Taek | - |
dc.contributor.author | Kim, Yong Hoon | - |
dc.contributor.author | Cha, Ji Yean | - |
dc.contributor.author | Park, Se Min | - |
dc.contributor.author | Park, Choon-Sik | - |
dc.date.accessioned | 2021-08-12T07:25:49Z | - |
dc.date.available | 2021-08-12T07:25:49Z | - |
dc.date.issued | 2010-01 | - |
dc.identifier.issn | 2092-7355 | - |
dc.identifier.issn | 2092-7363 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18111 | - |
dc.description.abstract | Purpose: Leukotriene receptor antagonists (LTRAs) are used to treat aspirin-intolerant asthma (AIA); however, the protective effects of long-term LTRA administration against aspirin-induced bronchospasm have not been evaluated. Objectives: We investigated the efficacy of a 12-week treatment with a LIRA in protecting against aspirin-induced asthma in AIA patients. Methods: Fifty-two adult patients with AIA underwent an aspirin challenge test just before administration of montelukast (10 mg/day) and just after 12 weeks of treatment. The protective effect was assessed as the disappearance of aspirin-induced bronchospasm after 12 weeks of treatment. The results were compared according to the patients' clinical and physiological parameters. Results: The decline in FEV1 following aspirin challenge was significantly reduced from 28.6 +/- 1.9% to 10.2 +/- 1.7% (P=0.0001) after 12 weeks of montelukast treatment. However, 14 subjects (30%) still showed a positive response (>15% decline in FEV1) to aspirin challenge. Grouping the subjects into good and poor responders according to post-treatment responses revealed that the pretreatment aspirin-induced FEV1 decline was significantly greater in the poor responders and that the triggering dose of aspirin and the induction time for a positive response were lower and shorter, respectively, in the poor responders. Histories of aspirin hypersensitivity and sinusitis were more prevalent among the poor responders than among the good responders. Conclusions: Twelve weeks of treatment with montelukast protected against aspirin-induced bronchospasm in 70% of the AIA cases. A poor response was associated with more severe aspirin-induced bronchospasms before treatment and a history of aspirin hypersensitivity or sinusitis. Clinical implications: A severe response to aspirin challenge may be a predictor of poor responsiveness to leukotriene antagonist treatment. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한천식알레르기학회 | - |
dc.title | Protection of leukotriene receptor antagonist against aspirin-induced bronchospasm in asthmatics | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4168/aair.2010.2.1.48 | - |
dc.identifier.scopusid | 2-s2.0-77952788524 | - |
dc.identifier.wosid | 000291503500007 | - |
dc.identifier.bibliographicCitation | Allergy, Asthma & Immunology Research, v.2, no.1, pp 48 - 54 | - |
dc.citation.title | Allergy, Asthma & Immunology Research | - |
dc.citation.volume | 2 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 48 | - |
dc.citation.endPage | 54 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001575109 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Allergy | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Allergy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | INTOLERANT ASTHMA | - |
dc.subject.keywordPlus | INFLAMMATORY CELLS | - |
dc.subject.keywordPlus | MODIFIER DRUGS | - |
dc.subject.keywordPlus | MONTELUKAST | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | HYPERSENSITIVITY | - |
dc.subject.keywordPlus | CHALLENGES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | RHINITIS | - |
dc.subject.keywordAuthor | Asthma | - |
dc.subject.keywordAuthor | leukotriene antagonists | - |
dc.subject.keywordAuthor | aspirin | - |
dc.subject.keywordAuthor | eosinophils | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.